- ATNM-400 exhibits superior efficacy with 3-5x greater tumor growth inhibition compared to front line therapy osimertinib (EGFR TKI TAGRISSO ®), second line therapy Dato-DXd (Trop-2 ADC DATROWAY ®) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback